Cooper Companies (NASDAQ:COO) Director Lawrence Erik Kurzius Buys 10,000 Shares of Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Kurzius purchased 10,000 shares of Cooper Companies stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $53.91 per share, with a total value of $539,100.00. Following the completion of the acquisition, the director owned 21,099 shares in the company, valued at $1,137,447.09. The trade was a 90.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Cooper Companies Stock Down 1.8%

NASDAQ:COO traded down $0.95 during mid-day trading on Tuesday, reaching $53.27. The stock had a trading volume of 4,408,999 shares, compared to its average volume of 2,501,526. The business’s 50 day moving average is $71.25 and its 200 day moving average is $69.40. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The stock has a market cap of $10.13 billion, a P/E ratio of 18.18, a PEG ratio of 2.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, sell-side analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its board has initiated a stock repurchase plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Cooper Companies in the second quarter valued at about $1,077,762,000. Generation Investment Management LLP bought a new stake in Cooper Companies during the 2nd quarter worth about $356,304,000. Jupiter Topco LLC bought a new stake in Cooper Companies during the 2nd quarter worth about $305,074,000. Diamond Hill Capital Management Inc. increased its position in Cooper Companies by 479.6% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 3,287,837 shares of the medical device company’s stock valued at $269,471,000 after acquiring an additional 2,720,594 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in Cooper Companies by 108.2% in the 4th quarter. Franklin Resources Inc. now owns 4,022,033 shares of the medical device company’s stock valued at $329,646,000 after acquiring an additional 2,089,763 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research report on Wednesday, May 27th. Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC lowered their price objective on Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a report on Thursday, September 10th. Zacks Research downgraded Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday. Finally, Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the company a “buy” rating in a research note on Thursday, September 10th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.